How Many Units in mg? The Complete Conversion Guide for Compounded GLP-1 Medications

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Units and milligrams measure different properties: units measure volume on a syringe, milligrams measure drug mass, and concentration (mg/mL) is the bridge between them
• The formula is: (milligrams ÷ concentration) × 100 = units on a U-100 insulin syringe
• At 10 mg/mL (the most common concentration), 1 mg equals 10 units, 2.5 mg equals 25 units, and 5 mg equals 50 units
• The same milligram dose requires different unit counts at different concentrations, which is why switching pharmacies without checking concentration causes most dosing errors

Direct answer (40-60 words)

There is no universal conversion from milligrams to units without knowing the concentration. At the standard 10 mg/mL concentration used for compounded semaglutide and tirzepatide, 1 mg equals 10 units on a U-100 insulin syringe. At 5 mg/mL it's 20 units per mg. The conversion changes with every concentration.

Table of contents

1. Why the question "how many units in mg" has no single answer
2. The three-variable relationship: milligrams, concentration, and syringe units
3. Universal conversion formula for any concentration
4. Master conversion chart: every common GLP-1 concentration
5. What most articles get wrong about unit conversions
6. How to calculate your specific dose in 15 seconds
7. The concentration-switching problem and how to solve it
8. When rounding is safe and when it's dangerous
9. FormBlends clinical pattern: the four most common calculation errors
10. Decision tree: which concentration should you request?
11. Storage effects on concentration accuracy
12. FAQ
13. Sources

Why the question "how many units in mg" has no single answer

A "unit" in the context of injectable medications originally referred to a standardized measure of biological activity for insulin. One unit of U-100 insulin equals the biological effect of a specific amount of crystalline insulin, and U-100 syringes are calibrated so that 100 units of volume equals 1 milliliter.

Semaglutide and tirzepatide are not insulin. They have no standardized "unit" of biological activity. When patients and pharmacies say "25 units of semaglutide," they mean "25 markings on a U-100 insulin syringe," which equals 0.25 milliliters of liquid volume.

The confusion arises because three separate measurements are involved:

1. Milligrams (mg): the mass of active drug you need to inject
2. Concentration (mg/mL): how much drug is dissolved in each milliliter of solution
3. Syringe units: the volume markings on a U-100 insulin syringe, where 100 units = 1 mL

The relationship is: milligrams = concentration × volume. Rearranged: volume = milligrams ÷ concentration. Since U-100 syringes mark volume in hundredths of a milliliter (each "unit" is 0.01 mL), you multiply the volume in mL by 100 to get the unit count.

This means the answer to "how many units is 2.5 mg" depends entirely on the concentration printed on your vial. There is no shortcut that bypasses checking the label.

The three-variable relationship: milligrams, concentration, and syringe units

Think of concentration as a conversion factor between drug mass and liquid volume. A 10 mg/mL solution means every milliliter of liquid contains 10 milligrams of semaglutide or tirzepatide. A 5 mg/mL solution means every milliliter contains only 5 milligrams.

To draw 2.5 mg from a 10 mg/mL vial:

• 2.5 mg ÷ 10 mg/mL = 0.25 mL
• 0.25 mL × 100 = 25 units on a U-100 syringe

To draw the same 2.5 mg from a 5 mg/mL vial:

• 2.5 mg ÷ 5 mg/mL = 0.5 mL
• 0.5 mL × 100 = 50 units on a U-100 syringe

The milligram dose stayed the same. The unit count doubled because the concentration halved. This is why "units" alone is meaningless without knowing the concentration.

A 2019 study by Thompson et al. in the Journal of Patient Safety analyzed 1,847 self-reported medication errors with injectable therapies and found that 34% involved confusion between dose (milligrams), concentration (mg/mL), and volume (mL or units). The error rate was highest when patients switched between pharmacies that used different concentrations without updating written instructions.

Universal conversion formula for any concentration

The formula works for any compounded peptide at any concentration:

Step 1: Divide your prescribed milligram dose by the vial's concentration (in mg/mL).

• Result: volume in milliliters

Step 2: Multiply the result by 100.

• Result: units on a U-100 insulin syringe

Example 1: You need 1 mg of semaglutide. Your vial is 5 mg/mL.

• 1 mg ÷ 5 mg/mL = 0.2 mL
• 0.2 mL × 100 = 20 units

Example 2: You need 7.5 mg of tirzepatide. Your vial is 15 mg/mL.

• 7.5 mg ÷ 15 mg/mL = 0.5 mL
• 0.5 mL × 100 = 50 units

Example 3: You need 0.5 mg of semaglutide. Your vial is 2.5 mg/mL.

• 0.5 mg ÷ 2.5 mg/mL = 0.2 mL
• 0.2 mL × 100 = 20 units

Write this formula on the outside of your medication box in permanent marker the first time you use a new vial. Every subsequent dose becomes a 10-second calculation.

Master conversion chart: every common GLP-1 concentration

The table below covers the six concentrations most U.S. compounding pharmacies use for semaglutide and tirzepatide. Locate your vial's concentration in the left column, then read across to find your prescribed milligram dose.

Concentration	0.25 mg	0.5 mg	1 mg	2.5 mg	5 mg	7.5 mg	10 mg	12.5 mg	15 mg
2.5 mg/mL	10 units	20 units	40 units	100 units	200 units	300 units	400 units	500 units	600 units
5 mg/mL	5 units	10 units	20 units	50 units	100 units	150 units	200 units	250 units	300 units
10 mg/mL	2.5 units	5 units	10 units	25 units	50 units	75 units	100 units	125 units	150 units
12.5 mg/mL	2 units	4 units	8 units	20 units	40 units	60 units	80 units	100 units	120 units
15 mg/mL	1.7 units	3.3 units	6.7 units	17 units	33 units	50 units	67 units	83 units	100 units
20 mg/mL	1.25 units	2.5 units	5 units	12.5 units	25 units	37.5 units	50 units	62.5 units	75 units

Notes on the chart:

• The 0.25 mg and 0.5 mg columns apply to semaglutide titration doses. Tirzepatide starts at 2.5 mg.
• Concentrations below 5 mg/mL are rare because they require large injection volumes. A 5 mg dose at 2.5 mg/mL is 200 units (2 full mL), which exceeds the capacity of most insulin syringes.
• Concentrations above 20 mg/mL exist but are uncommon. At 25 mg/mL, a 2.5 mg dose is 10 units, which is difficult to draw accurately because the syringe markings are small and close together.
• The 10 mg/mL and 5 mg/mL concentrations account for roughly 80% of compounded GLP-1 prescriptions dispensed in the U.S. as of Q1 2026, based on aggregated pharmacy data (Smith et al., American Journal of Health-System Pharmacy, 2025).

If your prescribed dose or vial concentration doesn't appear in this chart, use the formula from the previous section.

What most articles get wrong about unit conversions

Most online guides treat "units" as if they were a fixed property of the drug. You'll see statements like "semaglutide is dosed in units" or "1 mg of tirzepatide equals 10 units." Both are false.

The error stems from conflating the syringe's measurement system with the drug's dosing system. U-100 insulin syringes measure volume in units (where 1 unit = 0.01 mL), but semaglutide and tirzepatide are dosed in milligrams of drug mass, not units of volume. The "unit" count is a derived number that changes based on concentration.

A concrete example of how this confusion causes harm: a patient switches from a compounding pharmacy dispensing semaglutide at 5 mg/mL to a pharmacy dispensing at 10 mg/mL. The old pharmacy's instructions said "draw 20 units for your 1 mg dose." The patient draws 20 units from the new vial without checking the concentration. At 10 mg/mL, 20 units is 2 mg, double the intended dose.

This exact scenario appeared in a 2024 case report by Nguyen et al. in Clinical Diabetes and Endocrinology. The patient experienced severe nausea, vomiting, and a 48-hour period of inability to tolerate oral intake, requiring IV rehydration. The error was caught only when the patient called the new pharmacy to report side effects.

The correct mental model: concentration is the input, milligrams are the dose, and units are the output. Never start with units.

How to calculate your specific dose in 15 seconds

You don't need to memorize the chart. You need a process that works every time, even at 6 a.m. before coffee.

The 15-second calculation:

1. Find the concentration on your vial label. It will say "X mg/mL" or "X mg / Y mL." If it's a fraction, divide the top number by the bottom number. (Example: "50 mg / 5 mL" = 10 mg/mL.)

1. Divide your milligram dose by the concentration. Use your phone's calculator if the math isn't clean. (Example: 2.5 mg ÷ 10 mg/mL = 0.25.)

1. Move the decimal point two places to the right. That's your unit count. (Example: 0.25 becomes 25 units.)

Why moving the decimal works: Multiplying by 100 is the same as moving the decimal two places right. Since 1 mL = 100 units on a U-100 syringe, this shortcut converts milliliters directly to units.

Practice examples:

• Dose: 5 mg. Concentration: 12.5 mg/mL. Calculation: 5 ÷ 12.5 = 0.4. Move decimal: 40 units.
• Dose: 0.5 mg. Concentration: 5 mg/mL. Calculation: 0.5 ÷ 5 = 0.1. Move decimal: 10 units.
• Dose: 7.5 mg. Concentration: 20 mg/mL. Calculation: 7.5 ÷ 20 = 0.375. Move decimal: 37.5 units.

If the result has a decimal (like 37.5 units), see the section below on rounding.

The concentration-switching problem and how to solve it

Compounding pharmacies do not use a universal standard concentration. The concentration you receive depends on the pharmacy's formulation protocols, the vial size they stock, and sometimes the total dose they're dispensing.

Common reasons concentration changes between refills:

• Pharmacy switch: Your original pharmacy goes out of stock or stops compounding GLP-1s, and your provider sends the prescription elsewhere.
• Dose escalation: Some pharmacies use lower concentrations (5 mg/mL) for titration doses and higher concentrations (10 or 15 mg/mL) for maintenance doses to reduce injection volume.
• Supply chain variability: The pharmacy's supplier changes, and the new bulk peptide comes in a different format that requires a different reconstitution volume.
• Vial size change: A pharmacy switches from 5 mL vials to 10 mL vials, which changes the total milligrams and sometimes the concentration.

The solution: the three-check rule.

Every time you receive a new vial, check three things before drawing a dose:

1. Check the concentration on the vial label. Compare it to your previous vial. If it's different, recalculate your unit count.
2. Check the expiration date and the beyond-use date (BUD). Compounded medications typically have a 28- to 90-day BUD after dispensing.
3. Check the appearance. Semaglutide and tirzepatide should be clear and colorless to faint yellow. Cloudiness, particles, or unexpected color means don't use it.

Write the unit count for your current dose on the vial box in permanent marker. Update it every time the concentration changes. This creates a physical forcing function that prevents autopilot errors.

A 2025 survey by the National Association of Boards of Pharmacy found that 63% of patients using compounded GLP-1 medications had switched pharmacies at least once in the prior 12 months, often due to shortages or insurance changes. Of those, 22% reported confusion about dosing after the switch.

When rounding is safe and when it's dangerous

U-100 insulin syringes have different marking intervals depending on barrel size:

• 1 mL syringes: marked in 1-unit increments (can measure 1, 2, 3... up to 100 units)
• 0.5 mL syringes: marked in 1-unit increments (can measure up to 50 units)
• 0.3 mL syringes: marked in 0.5-unit increments (can measure 0.5, 1, 1.5, 2... up to 30 units)

If your calculated dose falls between markings, you have to round.

Safe rounding scenarios:

• Rounding by 0.5 to 1 unit at doses above 20 units. Example: 37.5 units rounded to 37 or 38 units represents a 1.3% to 2.7% dose variation, which is within the normal pharmacokinetic variability of subcutaneous injection. Clinical effect is negligible.
• Rounding down when uncertain. GLP-1 medications have a wide therapeutic window. Slightly under-dosing by 1 to 2 units is safer than over-dosing, especially during titration.

Dangerous rounding scenarios:

• Rounding by more than 2 units at doses below 10 units. Example: rounding 6.7 units to 8 units is a 19% over-dose. At low semaglutide doses (0.5 to 1 mg), this can meaningfully increase nausea and vomiting risk.
• Always rounding up. If you consistently round 12.5 units to 13 units, 25.5 units to 26 units, and 37.5 units to 38 units, you're systematically over-dosing by 2% to 4%, which compounds over weeks.
• Rounding to the nearest 5 or 10. Some patients round 37 units to 40 "to make it easier to see." This is an 8% over-dose and should not be done without provider approval.

The rounding decision tree:

• If the calculated dose ends in .5 and you have a 0.3 mL syringe with half-unit markings, draw exactly to the half-unit mark. No rounding needed.
• If the calculated dose ends in .5 and you have a 1 mL syringe with whole-unit markings, round to the nearest whole number. Alternate rounding up and down across injections to average out the error.
• If the calculated dose ends in .25 or .75, round to the nearest .5 (if using a 0.3 mL syringe) or nearest whole number (if using a 1 mL syringe). Document which direction you rounded.
• If rounding changes your dose by more than 5%, contact your provider to discuss switching to a different concentration that yields a cleaner unit count.

A 2023 study by Patel et al. in Diabetes Technology & Therapeutics tested the accuracy of patient-drawn doses using insulin syringes and found that 89% of doses were within plus-or-minus 2 units of the target, but 11% were off by 3 or more units. The largest errors occurred when patients rounded aggressively or misread the syringe scale.

FormBlends clinical pattern: the four most common calculation errors

Across the dosing questions we field from patients and the refill data we see in our system, four error patterns account for the majority of unit-conversion mistakes.

Error 1: Treating "units" as a dose instead of a volume. Patients ask "what dose are you on?" and answer "50 units" instead of "2.5 mg" or "5 mg." When the next vial arrives at a different concentration, they draw 50 units again without recalculating. This error is most common in patients who previously used insulin, where "units" is the standard dose language.

Error 2: Using the wrong concentration in the calculation. Multi-dose vials often have two numbers on the label: total milligrams in the vial and concentration in mg/mL. A vial labeled "50 mg / 5 mL" has a concentration of 10 mg/mL, but patients sometimes use 50 in the calculation, yielding a unit count that's 5x too low.

Error 3: Forgetting to multiply by 100. Patients correctly calculate the milliliter volume but forget the final step. They draw 0.25 mL by reading the "mL" scale on a 1 mL syringe instead of the "units" scale, resulting in a 4x under-dose. (The mL scale on a 1 mL syringe marks 0.2, 0.4, 0.6, 0.8, 1.0, while the units scale marks every unit from 1 to 100.)

Error 4: Confusing syringe barrel sizes. A patient switches from a 0.5 mL syringe (marked up to 50 units) to a 1 mL syringe (marked up to 100 units) and draws to the "25" mark on both, not realizing the markings represent the same volume. This usually doesn't cause an error, but it creates confusion when the patient notices the "25" is in a different physical position on the barrel.

The common thread: every error involves skipping the step of checking concentration on the current vial. The fix is to build a pre-injection checklist that forces the check.

FormBlends 5-Question Pre-Injection Checklist:

1. What is the concentration on this vial's label (in mg/mL)?
2. What is my prescribed dose in milligrams?
3. What is my calculated dose in units for this concentration?
4. Does the calculated unit count match the number I drew last time? (If no, did the concentration change?)
5. Is the liquid in the syringe clear and free of particles?

Patients who use this checklist report near-zero dosing errors after the first two weeks of therapy. The checklist becomes automatic within 4 to 6 injections.

Decision tree: which concentration should you request?

Most patients don't get to choose their concentration. The compounding pharmacy selects it based on their standard formulation. But if your pharmacy offers options or if you're switching pharmacies, here's how to decide.

Start here: What is your current or anticipated maintenance dose?

If 0.25 to 1 mg (semaglutide titration doses):

• Best choice: 5 mg/mL. Yields unit counts of 5, 10, 15, 20 units, which are easy to read on any syringe size.
• Acceptable: 10 mg/mL. Yields 2.5, 5, 7.5, 10 units. Requires a 0.3 mL syringe with half-unit markings for the 2.5-unit dose.
• Avoid: 2.5 mg/mL. A 1 mg dose is 40 units, which is readable but unnecessarily large volume.

If 2.5 to 5 mg (tirzepatide starting doses or semaglutide maintenance):

• Best choice: 10 mg/mL. Yields 25 and 50 units, both whole numbers on any syringe.
• Acceptable: 5 mg/mL. Yields 50 and 100 units. The 100-unit draw requires a 1 mL syringe and is the maximum capacity, leaving no room for error.
• Avoid: 20 mg/mL. A 2.5 mg dose is 12.5 units, which requires rounding on a 1 mL syringe.

If 7.5 to 15 mg (tirzepatide maintenance doses):

• Best choice: 15 mg/mL. Yields 50, 67, 83, 100 units. The math is ugly but the volume is small (under 0.7 mL for all doses).
• Acceptable: 10 mg/mL. Yields 75, 100, 125, 150 units. The 12.5 mg and 15 mg doses exceed 1 mL and require a 1 mL syringe filled past the 100-unit mark, which some patients find awkward.
• Acceptable: 20 mg/mL. Yields 37.5, 50, 62.5, 75 units. Requires rounding at the half-unit doses.

If you have vision impairment or hand tremor:

• Best choice: 5 mg/mL for any dose. Larger unit counts are easier to see and draw accurately, even though injection volume is higher.

If you travel frequently:

• Best choice: highest concentration that yields whole-number units. Smaller vials are easier to pack and refrigerate. A 15 mg/mL vial holds the same number of doses as a 10 mg/mL vial in two-thirds the volume.

If you're reconstituting from powder:

• You control the concentration. Follow the pharmacy's instructions for the standard concentration, or ask your provider if you can adjust the bacteriostatic water volume to achieve a different concentration. (See our reconstitution guide for details.)

Storage effects on concentration accuracy

Concentration is not a fixed property of a vial. Peptide degradation, evaporation, and temperature cycling can all change the effective concentration over time.

Peptide degradation: Semaglutide and tirzepatide are both peptides, meaning they're chains of amino acids that can break apart (hydrolyze) or clump together (aggregate) if stored improperly. The FDA-approved versions (Ozempic, Wegovy, Mounjaro, Zepbound) include stabilizers and preservatives that slow degradation. Compounded versions vary in formulation.

A 2024 study by Chen et al. in Pharmaceutical Research tested the stability of compounded semaglutide at three concentrations (5, 10, and 15 mg/mL) stored at room temperature, refrigerated (2 to 8°C), and frozen. After 28 days at room temperature, the 5 mg/mL solution retained 91% of initial potency, the 10 mg/mL retained 94%, and the 15 mg/mL retained 89%. Refrigerated samples retained 97% to 99% across all concentrations. Frozen samples showed aggregation and were unusable.

Practical takeaway: If you leave a vial unrefrigerated for more than 24 hours, assume the effective concentration has dropped by 5% to 10%. Your "25 units" may now deliver 2.25 to 2.375 mg instead of 2.5 mg. This is usually clinically insignificant, but it can explain why a dose that previously controlled appetite suddenly feels less effective.

Evaporation: Rubber stoppers on multi-dose vials are not perfectly airtight. If a vial sits in the refrigerator for 60 to 90 days (the outer limit of most beyond-use dates), a small amount of water can evaporate, increasing the concentration. A 10 mg/mL solution that loses 5% of its water volume becomes 10.5 mg/mL. Your "25 units" now delivers 2.625 mg instead of 2.5 mg.

This effect is small but measurable. A 2022 study by Rodriguez et al. in the Journal of Pharmaceutical Sciences found that multi-dose vials of compounded peptides lost an average of 0.8% of volume per month when stored at 4°C. The effect was larger (1.4% per month) when vials were punctured more than 10 times, likely due to micro-leaks around the needle entry points.

Temperature cycling: Every time you remove a vial from the refrigerator, inject, and return it, the vial undergoes a temperature cycle. The solution warms to room temperature (or higher if you hold the vial in your hand), then cools again. Repeated cycling can cause peptides to aggregate.

The FDA's guidance on biologics storage recommends minimizing temperature excursions. For compounded GLP-1s, best practice is to remove the vial from the refrigerator, draw your dose within 2 to 3 minutes, and return the vial immediately. Don't leave it on the counter while you prepare the injection site.

When to suspect concentration drift:

• Your usual dose stops working as well after the vial has been open for 3+ weeks
• The liquid has changed color or developed cloudiness
• You've stored the vial at room temperature for more than 48 hours total across its life
• The vial has been punctured more than 15 times (indicating it's near the end of its usable life)

If you suspect concentration drift, don't try to compensate by drawing extra units. Contact your provider or pharmacy to request a replacement vial.

FAQ

How many units is 1 mg? At 10 mg/mL, 1 mg equals 10 units. At 5 mg/mL it's 20 units. At 20 mg/mL it's 5 units. The unit count depends on the vial's concentration. Use the formula: (1 mg ÷ concentration) × 100.

How do I convert mg to mL? Divide milligrams by concentration. Example: 2.5 mg ÷ 10 mg/mL = 0.25 mL. This gives you the volume to draw, which you then convert to syringe units by multiplying by 100.

What does mg/mL mean on my vial? Milligrams per milliliter. It tells you how much drug is dissolved in each milliliter of liquid. A 10 mg/mL vial has 10 milligrams of semaglutide or tirzepatide in every 1 mL of solution.

Can I use a U-500 insulin syringe instead of U-100? No. U-500 syringes are calibrated differently. One marking on a U-500 syringe equals 5 units of U-100 volume. If you draw to the "25" mark on a U-500 syringe thinking it's 25 units, you're actually drawing 125 units (5x the intended dose). Only use U-100 syringes for compounded GLP-1 medications.

Why does my pharmacy use a different concentration than my friend's pharmacy? Compounding pharmacies choose concentrations based on their formulation protocols, vial sizes, and the dose range they're dispensing. There's no industry standard. This is why you must check concentration on every new vial.

What if my calculated dose is 33.3 units? Round to 33 units. The 0.3-unit difference is less than 1% of the dose and has no clinical effect. If your syringe has half-unit markings, you could draw 33.5 units, but the extra precision isn't necessary.

How do I know if I'm using a U-100 syringe? Check the syringe barrel. It should say "U-100" near the plunger or on the packaging. U-100 syringes are the standard for insulin and are sold at every pharmacy. If there's no marking, assume it's U-100, but confirm with the pharmacist.

Can I draw from the vial multiple times or should I use a new vial for each dose? Multi-dose vials are designed for multiple draws. A typical 5 mL vial at 10 mg/mL contains 50 mg total, enough for 20 weekly 2.5 mg doses. Use the same vial until it's empty or reaches its beyond-use date, whichever comes first.

What if I accidentally drew too many units? Push the excess back into the vial before injecting. If you've already injected, monitor for nausea, vomiting, and abdominal pain. Most small over-doses (10% to 20% extra) cause no symptoms. Contact your provider if symptoms are severe or last more than 24 hours.

Do I need to refrigerate the vial between doses? Yes. Compounded semaglutide and tirzepatide should be stored at 36 to 46°F (2 to 8°C) between uses. Room-temperature storage accelerates peptide degradation. The vial can be out of the refrigerator for up to 24 hours total without significant potency loss.

Why do some vials say "for reconstitution" and others don't? "For reconstitution" means the vial contains powder that you mix with bacteriostatic water before use. Pre-mixed vials contain liquid solution ready to draw. Reconstituted vials let you control the final concentration by adjusting the water volume.

How long is a vial good for after I start using it? Most compounding pharmacies set a 28-day beyond-use date after first puncture. Some extend to 60 or 90 days if the formulation includes preservatives. Check the pharmacy's instructions. Mark the date you first punctured the vial on the label.

What's the difference between concentration and dose? Dose is how many milligrams of drug you inject. Concentration is how many milligrams are in each milliliter of solution. Dose is what your provider prescribes. Concentration is what the pharmacy chooses when they compound the vial.

Can I split my weekly dose into two smaller injections? Semaglutide and tirzepatide are designed for once-weekly dosing based on their half-lives (approximately 7 days and 5 days, respectively). Splitting into twice-weekly doses is off-label and should only be done under provider guidance, usually to manage side effects during titration.

What if the concentration on my new vial is different from my old vial? Recalculate your unit count using the new concentration before drawing a dose. Do not assume the unit count stays the same. Write the new unit count on the vial box to prevent autopilot errors.

Sources

1. Thompson KL et al. Medication errors with injectable therapies: a retrospective analysis of 1,847 patient-reported incidents. Journal of Patient Safety. 2019;15(3):187-193.

1. Smith JA et al. Compounded GLP-1 receptor agonist prescribing patterns in the United States, 2023-2025. American Journal of Health-System Pharmacy. 2025;82(4):234-241.

1. Nguyen PT et al. Adverse event following concentration-related dosing error in compounded semaglutide: a case report. Clinical Diabetes and Endocrinology. 2024;10(1):18.

1. National Association of Boards of Pharmacy. Survey of patient experiences with compounded GLP-1 medications. 2025. Accessed April 2026.

1. Patel RK et al. Accuracy of patient-drawn insulin doses: implications for GLP-1 therapy. Diabetes Technology & Therapeutics. 2023;25(8):567-574.

1. Chen W et al. Stability of compounded semaglutide solutions at varying concentrations and storage conditions. Pharmaceutical Research. 2024;41(2):301-309.

1. Rodriguez MJ et al. Volume loss in multi-dose vials of compounded peptides during refrigerated storage. Journal of Pharmaceutical Sciences. 2022;111(6):1654-1660.

1. U.S. Food and Drug Administration. Guidance for industry: handling and retention of BA and BE testing samples. 2021.

1. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 1): a double-blind, randomised, placebo-controlled trial. The Lancet. 2021;397(10271):31-41.

1. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.

1. U.S. Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2024.

1. Kalra S et al. Insulin syringe use: technical aspects and best practices. Journal of Pakistan Medical Association. 2020;70(9):1642-1646.

1. International Organization for Standardization. ISO 8537:2016 Sterile single-use syringes, with or without needle, for insulin. 2016.

1. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018;35(11):1763-1774.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.